The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide

Group 1 - Hims & Hers (NYSE: HIMS) stock has increased approximately 70% since the buy recommendation on November 16, 2024, as of March 19 [1] - The author has a background in engineering and a strong interest in investing, particularly in tech stocks [1] Group 2 - No stock, option, or similar derivative positions are held in any of the companies mentioned, and there are no plans to initiate such positions within the next 72 hours [1]